AMBITION

Ambrisentan and Tadalafil in Patients with Pulmonary Arterial Hypertension

Paciente / Población Intervención / Exposición Comparación Desenlace

In 500 patients with pulmonary arterial hypertension, initial ambrisentan plus tadalafil reduced clinical-failure events compared with monotherapy.

500

Diseño

Double-blind RCT

Desenlace

First clinical-failure event

Relevancia

ResultadoHR 0.50 for the primary composite.

Galiè N, et al. N Engl J Med. 2015;373(9):834-844. 10.1056/NEJMoa1413687

Discusión y crítica

Established upfront dual combination therapy as the standard initial approach for most patients with PAH.